Jamie Dimon says a recession is ‘likely outcome’ from Trump’s tariff turmoil

Jamie Dimon says a recession is ‘likely outcome’ from Trump’s tariff turmoil


Jamie Dimon, Chairman and Chief Executive officer (CEO) of JPMorgan Chase & Co. (JPM) speaks to the Economic Club of New York in Manhattan in New York City, U.S., April 23, 2024.

Mike Segar | Reuters

JPMorgan Chase CEO Jamie Dimon said Wednesday he sees the U.S. economy likely headed to recession as President Donald Trump’s tariffs roil financial markets.

With the trade war between the U.S. and China intensifying, stocks and bonds sold off aggressively again in morning trade. Stock market futures slumped and bond yields spiked amid concerns over financial and economic stability brought on by the tit-for-tat exchange between the two nations.

“I think probably [a recession is] a likely outcome,” Dimon said on Fox Business’ “Mornings With Maria” show.

Recession fears have been rising on Wall Street as the Trump tariffs spur uncertainty about how far the trade war will escalate.

In the latest development, China said it will slap an 84% tariff on all U.S. goods, up 50 percentage points from the previous level, as U.S. reciprocal duties take effect around the world. Dow futures were off more than 800 points while the 10-year Treasury yields soared nearly 20 basis points, or 0.2 percentage point.

JPMorgan economists expect U.S. gross domestic product to contract 0.3% this year, a mild recessionary call but coming after a strong year for growth.

“Markets aren’t always right, but sometimes they are right,” Dimon said. “I think this time they are right because they’re just pricing uncertainty [at] the macro level and uncertainty [at] the micro level, at the actual company level, and then how it affects consumer sentiment. It’s hard to tell.”

In the past, Dimon has been a supporter of tariffs.

During a January interview with CNBC at the World Economic Forum in Davos, Switzerland, the executive said people should “get over it” regarding tariffs and said a little inflation would be worth it to preserve national security.

On Wednesday, he encouraged the U.S. to make deals with its trading partners while cautioning that market reaction could get worse if that doesn’t happen.

“Take a deep breath, negotiate some trade deals. That’s the best thing they can do,” he said. “I’m taking a calm view. But I think it could get worse if we don’t make some progress here.”

Separately, Dimon encouraged the Senate to confirm Fed Governor Michelle Bowman as vice chair for supervision, the chief overseer of the banking and finance system. Bowman is up for a confirmation hearing Thursday.

Correction: An earlier version contained quotes misattributed to Jamie Dimon.

Don’t miss these insights from CNBC PRO



Source

Italy investigates Sephora and Benefit over skincare marketing to children
World

Italy investigates Sephora and Benefit over skincare marketing to children

A view of a Sephora beauty product store on May 30, 2025 in Sherman Oaks, California. Justin Sullivan | Getty Images Italian regulators are looking to clamp down on the tween skincare obsession and are investigating the LVMH-owned cosmetic brands Sephora and Benefit over an “insidious” marketing campaign to children. The Italian Competition Authority (AGCM) […]

Read More
Economist Nouriel Roubini: Trump is likely to escalate the Iran war — risking ‘1970s stagflation’
World

Economist Nouriel Roubini: Trump is likely to escalate the Iran war — risking ‘1970s stagflation’

U.S. President Donald Trump is likely to escalate the war with Iran, risking “1970s stagflation” if it does not go as planned, renowned economist and investor Nouriel Roubini told CNBC. Speaking to CNBC’s Carolin Roth at the Ambrosetti Forum in Cernobbio, Italy on Friday, Roubini — best known for predicting the 2008 Global Financial Crisis […]

Read More
AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed
World

AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed

AstraZeneca‘s stock jumped nearly 5% after Britain’s most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment tozorakimab, reduced flare-ups of chronic obstructive pulmonary disease (COPD) in both former smokers and in the overall population versus placebo, the company said. “This marks a notable shift […]

Read More